Atlas Venture is a venture capital firm that invests in early-stage biotech and life sciences companies. The firm supports entrepreneurial teams in creating and developing novel therapies to address unmet medical needs.

Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. 

Bicycle Therapeutics

Alnylam Pharmaceuticals

Avrobio

Kymera Therapeutics

Viridian Therapeutics

MorphoSys

DraftKings

Drizly

Earnest

Skillz

Spero Therapeutics

Synlogic

Currencycloud

Third Harmonic Bio

Veracode

InsightSquared

Integral Ad Science

Nimbus Therapeutics

PillPack

Privy

Translate Bio

Replimune Group

Intellia Therapeutics

Renaissance Venture Capital

Noteworthy news out of Nvelop Therapeutics as they launch with $100M to advance research in gene editing using programmable, non-viral delivery platforms built on two in vivo validated approaches.

https://lnkd.in/ej9ErVke

The 2024 #Science2Startup symposium is tomorrow! After exciting discussions and powerful networking, 8 researchers will present their ideas and interact with leading investors and executives in the Boston #biotech hub.

Thank you to our other event hosts F-Prime Capital, 5AM Ventures, Osage University Partners (OUP), RA Capital Management, and MassBio. 

Make sure to follow along for updates!

Thank you to #Science2Startup sponsor Colliers for hosting this year's academic workshop, “Business Plan must guide the Real Estate, not the other way around,” presented by Evan Gallagher, Colliers Executive Vice President & Director of Life Sciences Practice, and Caitlin Mahoney, Colliers Life Sciences Advisor. 
 
As a sponsor, you have the unique opportunity to showcase your domain knowledge in the industry with the potential to become the key partner for the startups throughout their company life cycle.
 
To learn more about the event or to get involved, please email us at info@science2startup.com or visit www.science2startup.com.
  
#biotech #pharma #startup

Thank you to #Science2Startup sponsor Silicon Valley Bank for hosting this year's academic workshop, “Banking Innovation: Considerations for Early-Stage Life Science Companies,” presented by Nathan Meaux, Silicon Valley Bank Director, Head of Northeast Bio, Relationship Management, and Michael Ritter, Silicon Valley Bank Vice President, Early-Stage Biopharma, Relationship Management.
 
As a sponsor, you have the unique opportunity to showcase your domain knowledge in the industry with the potential to become the key partner for the startups throughout their company life cycle.
 
To learn more about the event or to get involved, please email us at info@science2startup.com or visit www.science2startup.com.
  
#biotech #pharma #startup

We are delighted to introduce Evan Gallagher, Executive Vice President of Colliers, who will serve as an advisor for #Science2Startup taking place at the Broad Institute on April 10th. 
 
Evan Gallagher is a veteran life science real estate advisor specializing in tenant representation in all the Greater Boston lab clusters. His in-depth market knowledge of lab and GMP space, relationships throughout the life science industry and deep experience representing biotech companies in the area sets him apart from other real estate advisors in the market.

Evan is widely known for being a frontrunner in the life science real estate industry in the Boston area. An extremely strong advocate and negotiator on behalf of his clients, Evan built the Life Science Practice Team at Colliers’ Boston office and is well-versed in all aspects of design and construction of laboratory and GMP manufacturing facilities.

Evan has represented 200+ life science companies throughout his 20-year career.

Learn more about the advisors, the symposium and the firms supporting the future of the #biotech industry here: science2startup.com

An incredibly exciting day for Diagonal Therapeutics as they launch with $128M in financing to advance a ground-breaking approach to agonist antibody therapeutics aimed at treating the underlying causes of debilitating diseases. 

Congrats to Alexey "Alex" Lugovskoy and the entire Diagonal team!

https://lnkd.in/ece8H5Hw

COM:ATLASVENTURE

Atlas Venture

Financials Not Available